argenx SE ARGX

$835.99 -0.30%

Profile

argenx SE, a commercial-stage biopharma company, develops various therapies for the treatment of autoimmune diseases in the United States, Japan, China, the Netherlands, and internationally. The company offers VYVGART for the treatment of gMG and immune thrombocytopenia (ITP), and VYVGART HYTRULO for the treatment of gMG and chronic inflammatory demyelinating polyneuropathy (CIDP). It also develops efgartigimod for the treatment of seronegative gMG, ocular myasthenia gravis (MG), primary ITP, grave's disease, myositis, Sjögren's disease, systemic sclerosis, and AMR; empasiprubart for MMN, delayed graft function, and CIDP; and adimanebart for congenital myasthenic syndrome and spinal muscular atrophy. In addition, the company is developing ARGX-213, a neonatal Fc receptor (FcRn)-targeted antibody engineered for half-life extension and sustained IgG reduction; ARGX-124, a FcRn pipeline candidate; ARGX-109, which targets IL-6 to treat inflammation; ARGX-121, which targets immunoglobulin A; and ARGX-118, which develops antibodies against Galectin-10, as well as cusatuzumab, ARGX-112, ARGX-114, and ARGX-115. It has strategic partnerships and license agreements with Zai Lab to develop and commercialize efgartigimod; Halozyme Therapeutics to its ENHANZE for the prevention and treatment of human diseases; OncoVerity, Inc for cusatuzumab; and AbbVie, Inc. for ARGX-115. argenx SE was incorporated in 2008 and is based in Amsterdam, the Netherlands.

Key Stats

산업 (Industry) Biotechnology
시가총액 (Mkt Cap) 522B
PER 37.07
PBR 176.61
PSR (TTM) 11.02
EPS (TTM) 22.55
배당수익률 (Div. Yield) %
Sector Healthcare
52주 최고가 $934.62
52주 최저가 $510.06
52주 평균 $780.14
200일 평균 $797.95
거래량 (Volume) 191,916
상장주식수 62,187,771

Company Metrics

AI 예측 정확도

모델 매매 수익률

(복리 적용)

총 예측 횟수

날짜 AI 시그널 실제 결과 변동률 성공